16.98
-0.96 (-5.35%)
| Penutupan Terdahulu | 17.94 |
| Buka | 17.12 |
| Jumlah Dagangan | 632,963 |
| Purata Dagangan (3B) | 902,262 |
| Modal Pasaran | 1,866,356,608 |
| Harga / Jualan (P/S) | 3.03 |
| Harga / Buku (P/B) | 5.12 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Apr 2025 |
| Margin Keuntungan | -27.86% |
| Margin Operasi (TTM) | -38.66% |
| EPS Cair (TTM) | -1.56 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 20.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 189.72% |
| Nisbah Semasa (MRQ) | 1.46 |
| Aliran Tunai Operasi (OCF TTM) | -26.37 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 9.29 M |
| Pulangan Atas Aset (ROA TTM) | -8.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -46.67% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | NovoCure Limited | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.63 |
|
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 9.73% |
| % Dimiliki oleh Institusi | 87.41% |
| Julat 52 Minggu | ||
| Median | 38.00 (123.79%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 14 Jan 2025 | 38.00 (123.79%) | Beli | 26.23 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 Apr 2025 | Pengumuman | Novocure to Report First Quarter 2025 Financial Results |
| 04 Mar 2025 | Pengumuman | Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference |
| 27 Feb 2025 | Pengumuman | Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update |
| 22 Jan 2025 | Pengumuman | Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland |
| 13 Jan 2025 | Pengumuman | Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |